```
=> b reg
FILE 'REGISTRY' ENTERED AT 13:45:06 ON 01 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 JUN 2010  HIGHEST RN 1228750-08-0
DICTIONARY FILE UPDATES:  30 JUN 2010  HIGHEST RN 1228750-08-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l5
L3              STR
```




```
VAR G1=O/S
VAR G2=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L5         1668 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED    7786 ITERATIONS                          1668 ANSWERS
SEARCH TIME: 00.00.01


=> d que sta l13
L3              STR
```



VAR G1=O/S
VAR G2=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L5 1668 SEA FILE=REGISTRY SSS FUL L3
L11 STR



VAR G1=O/S
VAR G2=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L13 233 SEA FILE=REGISTRY SUB=L5 SSS FUL L11

100.0% PROCESSED 233 ITERATIONS 233 ANSWERS
SEARCH TIME: 00.00.01

=> d que sta l26
L24 STR



REP G1=(0-2) C
VAR G2=O/S
VAR G3=C/N
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE
L26 265 SEA FILE=REGISTRY SSS FUL L24

100.0% PROCESSED 1481 ITERATIONS 265 ANSWERS

SEARCH TIME: 00.00.01

=> b zcap
FILE 'ZCAPLUS' ENTERED AT 13:45:19 ON 01 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Jul 2010 VOL 153 ISS 1
FILE LAST UPDATED: 30 Jun 2010 (20100630/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitstr l30 tot

L30 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:472150 ZCAPLUS

DN 143:26626

TI Preparation of aminoquinazolidinedione derivatives as antibacterials.

IN Ellsworth, Edmund Lee; Hoyer, Denton Wade; Hutchings, Kim Marie; Kendall, Jackie Diane; Murphy, Sean Timothy; Starr, Jeremy Tyson; Tran, Tuan Phong

PA Warner-Lambert Company LLC, USA

SO PCT Int. Appl., 226 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005049605	A1	20050602	2004WO-IB003645	20041105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2546339	A1	20050602	2004CA-002546339	20041105
EP-----1687296	A1	20060809	2004EP-000798793	20041105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR--2004016708	A	20070116	2004BR-000016708	20041105
JP--2007511597	T	20070510	2006JP-000540639	20041105
MX--2006005550	A	20060817	2006MX-000005550	20060516
US-20070191333	A1	20070816	2007US-000580088	20070227
PRAI 2003US-00523072P	P	20031118		
2004US-00606442P	P	20040902		
2004WO-IB003645	W	20041105		

OS CASREACT 143:26626; MARPAT 143:26626

GI



I

AB Title compds. [I; A = specified (fused) cyanoethylaminopyrrolidinyl, etc.; X = N, C; R1 = alkyl, cycloalkyl, haloalkyl, halocycloalkyl, aryl, heteroaryl, cycloalkylalkyl; R2 = H, NH2, NHP(O)(OH)2, alkylamino, cycloalkylamino, arylamino, heteroarylamino, etc.; R3-R5 = H, halo, amino, alkyl, haloalkyl, alkoxy, haloalkoxy, cyano; R1R5 = atoms to form a 5-6 membered (substituted) ring], were prepared Thus, 3-amino-3-pyrrolidin-3-ylpropionitrile, 3-amino-1-cyclopropyl-6,7-difluoro-8-methyl-1H-quinazoline-2,4-dione, and 1,1,3,3-tetramethylguanidine were heated together at 90° overnight to give 37% 3-amino-3-[1-(1-cyclopropyl-6-fluoro-8-methyl-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-7-yl)pyrrolidin-3-yl]propionitrile. The latter showed a min. inhibitory concentration of 2 μg/mL against H. influenzae HI-3542.

IT **852653-45-3P** **852653-46-4P** **852653-47-5P**
852653-48-6P **852653-49-7P** **852653-50-0P**
852653-51-1P **852653-52-2P** **852653-53-3P**
852653-54-4P **852653-55-5P** **852653-56-6P**
852653-57-7P **852653-58-8P** **852653-59-9P**
852653-60-2P **852653-61-3P** **852653-62-4P**
852653-63-5P **852653-64-6P** **852653-65-7P**

L30 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(drug candidate; prepn. of aminoquinazolidinediones as antibacterials)

IT **852656-26-9** **852656-27-0** **852656-28-1**
852656-29-2 **852656-30-5** **852656-31-6**
852656-32-7 **852656-33-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; preparation of aminoquinazolidinediones as antibacterials)

IT **852656-00-9P** **852656-01-0P** **852656-02-2P**
852656-04-3P **852656-05-4P** **852656-06-5P**
852656-07-6P **852656-08-7P** **852656-09-8P**
852656-10-1P **852656-11-2P** **852656-12-3P**
852656-13-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminoquinazolidinediones as antibacterials)

IT **852656-18-9P** **852656-19-0P** **852656-20-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoquinazolidinediones as antibacterials)

IT **852653-45-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminoquinazolidinediones as antibacterials)

RN 852653-45-3 ZCAPLUS

CN Propanenitrile, 3-[[[1-(3-amino-1-cyclopropyl-6-fluoro-1,2,3,4-tetrahydro-8-methoxy-2,4-dioxo-7-quinazolinyl)-3-pyrrolidinyl]methyl]amino]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)

852653-66-8P **852653-67-9P** **852653-68-0P**
852653-69-1P **852653-70-4P** **852653-71-5P**
852653-72-6P **852653-73-7P** **852653-74-8P**
852653-75-9P **852653-76-0P** **852653-77-1P**
852653-78-2P **852653-79-3P** **852653-80-6P**
852653-81-7P **852653-82-8P** **852653-83-9P**
852653-84-0P **852653-85-1P** **852653-86-2P**
852653-87-3P **852653-88-4P** **852653-89-5P**
852653-90-8P **852653-91-9P** **852653-92-0P**
852653-93-1P **852653-94-2P** **852653-95-3P**
852653-96-4P **852653-97-5P** **852653-98-6P**
852653-99-7P **852654-00-3P** **852654-01-4P**
852654-02-5P **852654-03-6P** **852654-04-7P**
852654-05-8P **852654-06-9P** **852654-07-0P**
852654-08-1P **852654-09-2P** **852654-10-5P**
852654-11-6P **852654-12-7P** **852654-13-8P**
852654-14-9P **852654-15-0P** **852654-16-1P**
852654-17-2P **852654-18-3P** **852654-19-4P**
852654-20-7P **852654-21-8P** **852654-22-9P**
852654-23-0P **852654-24-1P** **852654-25-2P**
852654-26-3P **852654-27-4P** **852654-28-5P**
852654-29-6P **852654-30-9P** **852654-31-0P**
852654-32-1P **852654-33-2P** **852654-34-3P**
852654-35-4P **852654-36-5P** **852654-37-6P**
852654-38-7P **852654-39-8P** **852654-40-1P**
852654-41-2P **852654-42-3P** **852654-43-4P**
852654-44-5P **852654-45-6P** **852654-46-7P**
852654-47-8P **852654-48-9P** **852654-49-0P**
852654-50-3P **852654-51-4P** **852654-52-5P**
852654-53-6P **852654-54-7P** **852654-55-8P**
852654-56-9P **852654-57-0P** **852654-58-1P**
852654-59-2P **852654-60-5P** **852654-61-6P**
852654-62-7P **852654-63-8P** **852654-64-9P**
852654-65-0P **852654-66-1P** **852654-67-2P**
852654-68-3P **852654-69-4P** **852654-70-7P**
852654-71-8P **852654-72-9P** **852654-73-0P**
852654-74-1P **852654-75-2P** **852654-76-3P**
852654-77-4P **852654-78-5P** **852654-79-6P**
852654-80-9P **852654-81-0P** **852654-82-1P**
852654-83-2P **852654-84-3P** **852654-85-4P**
852654-86-5P **852654-87-6P** **852654-88-7P**
852654-89-8P **852654-90-1P** **852654-91-2P**
852654-92-3P **852654-93-4P** **852654-94-5P**
852654-95-6P **852654-96-7P** **852654-97-8P**
852654-98-9P **852654-99-0P** **852655-00-6P**
852655-01-7P **852655-02-8P** **852655-03-9P**
852655-04-0P **852655-05-1P** **852655-06-2P**
852655-07-3P **852655-08-4P** **852655-09-5P**
852655-10-8P **852655-11-9P** **852655-12-0P**
852655-13-1P **852655-14-2P** **852655-15-3P**
852655-16-4P **852655-17-5P** **852655-18-6P**
852655-19-7P **852655-20-0P** **852655-21-1P**
852655-22-2P **852655-23-3P** **852655-24-4P**
852655-25-5P **852655-26-6P** **852655-27-7P**
852655-28-8P **852655-29-9P** **852655-30-2P**
852655-31-3P **852655-32-4P** **852655-33-5P**
852655-34-6P **852655-35-7P** **852655-36-8P**
852655-37-9P **852655-38-0P** **852655-39-1P**
852655-40-4P **852655-41-5P** **852655-42-6P**
852655-43-7P **852655-44-8P** **852655-45-9P**
852655-46-0P **852655-47-1P** **852655-48-2P**
852655-49-3P **852655-50-6P** **852655-51-7P**
852655-52-8P **852655-53-9P** **852655-54-0P**
852655-55-1P **852655-56-2P** **852655-57-3P**
852655-58-4P **852655-59-5P** **852655-60-8P**
852655-61-9P **852655-62-0P** **852655-63-1P**
852656-47-4P **852656-48-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

=> d bib abs hitstr l33 tot

L33 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2008:1215403 ZCAPLUS
DN 149:448422
TI Preparation of 7-amino-6-(aminomethyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives as renin inhibitors
IN Gwaltney, Stephen L.; Lam, Betty; Zhang, Zhiyuan
PA Takeda Pharmaceutical Company Limited, Japan
SO PCT Int. Appl., 208pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2008121506	A2	20081009	2008WO-US0056509	20080311
WO--2008121506	A3	20090219		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US-20100137310	A1	20100603	2009US-000529167	20090922
PRAI 2007US-00909382P	P	20070330		
2008WO-US0056509	W	20080311		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 149:448422; MARPAT 149:448422
GI



I



II

AB The invention is related to the preparation of title compds. I (Q = O, S, NH and derivs.; Y = CO, CS, SO, SO2, CH2 and derivs., C(NH2) and derivs.; R1 = H, CN, (un)substituted cyvcloalkyl, (hetero)aryl, etc.; R2 = CN, (un)substituted aminoalkyl, heterocycloalkyl, heterobicycloaryl, heteroaryl; R5, R7 = independently H, NH2, OH, (un)substituted alkyl, (hetero)arylalkyl, etc.; or R5 = absent when the N on which R5 is attached forms part of a double bond; R12 = (un)substituted Ph,

L33 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2007:1034380 ZCAPLUS
DN 149:288739
TI Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine as antitumor effect
AU Eissa, A. M. F.; Ezz El-Arab, E. M.; Farag, A. M.; Moharram, H. H.
CS Chemistry Department, Faculty of Science, Benha University, Egypt
SO Egyptian Journal of Chemistry (2006), 49(6), 761-774
CODEN: EGJCA3; ISSN: 0449-2285
PB National Information and Documentation Centre
DT Journal
LA English
OS CASREACT 149:288739
AB 6-Amino-3,5-dicyano-4-R-1,2-dihydropyridine-2-thiones (R = H, furan-2-yl, thien-2-yl, 3,4-(MeO)2C6H3) were used for the synthesis of diverse pyridopyrimidine derivs. of anticipated medicinal application, particularly their antitumor effect. The pyrido[2,3-d]pyrimidine ring system has been the subject of numerous studies because of its structural similarity to folic acid.
IT **1048986-95-3P** **1048986-97-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and evaluation of pyrido[2,3-d]pyrimidinecarbonitriles for antitumor activity)
RN 1048986-95-3 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carbonitrile, 5-(2-furanyl)-1,2,3,4-tetrahydro-7-(1-piperidinyl)-2,4-dithioxo- (CA INDEX NAME)



RN 1048986-97-5 ZCAPLUS
CN Pyrido[2,3-d]pyrimidine-6-carbonitrile, 5-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydro-7-(1-piperidinyl)-2,4-dithioxo- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 1 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
phenyl/naphthyl/alkyl] which exhibit renin and other S9 proteases activities, to their pharmaceutical compns., and kits. Synthetic examples in which R12 = H are also given. Thus, dioxopyridopyrimidine II was prepd. from 3,5-dimethoxybenzaldehyde, malononitrile, 6-amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione and 2-(bromomethyl)naphthalene and inhibited renin and DPP-IV with IC50 values in the range of 1-10 μM and >100 μM. I and their formulations are useful for treating cardiovascular diseases (no data).
IT **873935-46-7P**, 2-(6-(Aminomethyl)-1,3-dimethyl-2,4-dioxo-7-(pyrrolidin-1-yl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl)-5-chlorobenzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of dioxopyrido[2,3-d]pyrimidines derivs. as renin inhibitors)
RN 873935-46-7 ZCAPLUS
CN Benzonitrile, 2-(6-(aminomethyl)-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-7-(1-pyrrolidinyl)pyrido[2,3-d]pyrimidin-5-yl)-5-chloro- (CA INDEX NAME)



L33 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2006:53679 ZCAPLUS
DN 144:150378
TI Preparation of pyrido[2,3-d]pyrimidine-2,4-diones and related compounds as selective dipeptidyl peptidase inhibitors
IN Feng, Jun; Gwaltney, Stephen L.; Lam, Betty; Zhang, Zhiyuan
PA Takeda Pharmaceutical Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 55 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-20060014764	A1	20060119	2005US-000183335	20050715
WO--2006019965	A2	20060223	2005WO-US0025070	20050714
WO--2006019965	A3	20060406		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO--2006020017	A2	20060223	2005WO-US0025153	20050715
WO--2006020017	A3	20060727		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP-----1773832	A2	20070418	2005EP-000772260	20050715
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP--2008506708	T	20080306	2007JP-000521673	20050715
PRAI 2004US-00588577P	P	20040716		
2005WO-US0025153	W	20050715		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 144:150378; MARPAT 144:150378
GI



I II

AB Pyrido[2,3-d]pyrimidine-2,4-diones and related compds. (shown as I; variables defined below; e.g. 7-amino-6-aminomethyl-5-(2,4-dichlorophenyl)-1,3-dimethyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione trifluoroacetate (free

L33 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
base shown as II)), pharmaceutical compns., kits and methods are provided for inhibiting DPP-IV and other S9 proteases. Although the methods of prepn. are not claimed, prepns. and/or characterization data for .apprx.50 examples of I are included. For example, II was prepd. by cyclizing 2-(2,4-dichlorobenzylidene)malononitrile (prepd. from 2,4-dichlorobenzaldehyde and malononitrile) with 6-amino-1,3-dimethyluracil followed by redn. with BH3-THF and acidification with TFA. For I: W = CR3 and N; X = CR4 and N; Y = CO, CS, SO, SO2, CR6R6' and C:NR6; Z = CO, CS, SO, SO2, and C:NR6; R1 = (C1-10)alkyl, (C3-12)cycloalkyl, hetero(C3-12)cycloalkyl, aryl(C1-10)alkyl, heteroaryl(C1-5)alkyl, et al.; R2 = amino(C1-6)alkyl, hetero(C3-12)cycloalkyl, hetero(C4-12)bicycloaryl, heteroaryl, and cyano; R5 and R7 = H, halo(C1-10)alkyl, amino, nitro, thio, sulfonamide, (C1-10)alkyl, (C3-12)cycloalkyl, et al.; addnl. details including provisos are given in the claims. Compds. I were tested according to assays for protease inhibition and obsd. to exhibit selective DPP-IV inhibitory activity. For example, they inhibit DPP-IV activity at concns. that are at least 50 fold less than those concns. required to produce an equiactive inhibition of protease activity for FAPα. The apparent inhibition consts. (Ki) for compds. of the invention, against DPP-IV, were .apprx.10-9 M to .apprx.10-5 M.

IT **873935-46-7P**, 2-[6-(Aminomethyl)-1,3-dimethyl-2,4-dioxo-7-(pyrrolidin-1-yl)-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-5-yl]-5-chlorobenzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrido[2,3-d]pyrimidine-2,4-diones and related compds. as selective dipeptidyl peptidase inhibitors)

RN 873935-46-7 ZCAPLUS

CN Benzonitrile, 2-[6-(aminomethyl)-1,2,3,4-tetrahydro-1,3-dimethyl-2,4-dioxo-7-(1-pyrrolidinyl)pyrido[2,3-d]pyrimidin-5-yl]-5-chloro- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L33 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN
AN 2001:545673 ZCAPLUS
DN 135:122511
TI Preparation of 3-aminoquinazoline-2,4-dione antibacterial agents
IN Bird, Paul; Ellsworth, Edmund Lee; Nguyen, Dai Quoc; Sanchez, Joseph Peter; Showalter, Howard Daniel Hollis; Singh, Rajeshwar; Stier, Michael Andrew; Tran, Tuan Phong; Watson, Brian Morgan; Yip, Judy
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 291 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2001053273	A1	20010726	2000WO-US0033656	20001212 <--
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA-----2393802	A1	20010726	2000CA-002393802	20001212 <--
BR--2000017010	A	20021105	2000BR-000017010	20001212 <--
EP-----1255739	A1	20021113	2000EP-000984246	20001212 <--
EP-----1255739	B1	20080611		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU--2002004101	A2	20030428	2002HU-000004101	20001212 <--
HU--2002004101	A3	20040528		
JP--2003520277	T	20030702	2001JP-000553275	20001212 <--
EE--2002000412	A	20031015	2002EE-000000412	20001212 <--
AU------783078	B2	20050922	2001AU-000020899	20001212 <--
AT------398110	T	20080715	2000AT-000984246	20001212 <--
ES-----2304992	T3	20081101	2000ES-000984246	20001212 <--
IN---200200775	A	20050304	2002IN-000000775	20020612 <--
MX--2002005989	A	20021023	2002MX-000005989	20020614 <--
ZA--2002005197	A	20031104	2002ZA-000005197	20020627 <--
NO--2002003516	A	20020723	2002NO-000003516	20020723 <--
BG------107023	A	20030430	2002BG-000107023	20020822 <--
HR--2002000696	A2	20031231	2002HR-000000696	20020823 <--
US-20060183762	A1	20060817	2002US-000182221	20021209 <--
US-----7094780	B2	20060822		
US-20060287308	A1	20061221	2006US-000452121	20060613 <--
US-----7582627	B2	20090901		
PRAI 2000US-00178252P	P	20000124	<--	
2000US-00241267P	P	20001018	<--	
2000WO-US0033656	W	20001212	<--	
2002US-000182221	A3	20021209	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 135:122511
GI



AB Title compds. (I) [wherein: R1 and R3 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aryl, or heterocyclic; independently R5, R6, and R8 = H or (un)substituted alkyl, alkenyl, alkynyl, or halo, NO2, CN, NH2, (di)alkylamino, etc.; or R1 and R8 taken

L33 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)
together with the atoms to which they are attached may form an (un)substituted heterocycle; R7 = H or (un)substituted alkyl, alkenyl, alkynyl, (fused) heterocyclic, or (fused) aryl, or halo, NO2, CN, NH2, (di)alkylamino, carboxy, etc.; J and K = independently C or N; and pharmaceutically acceptable salts thereof] were prepd. as antibacterial agents. For example, N'-{4-[3-(tert-butoxycarbonylaminomethyl)pyrrolidin-1-yl]-2-cyclopropylamino-5-fluorobenzoyl}hydrazinecarboxylic acid tert-Bu ester (multi-step prepn. given) was chlorinated with N-chlorosuccinimide, cyclized with triphosgene in the presence of K2CO3, and deprotected using HCl gas to afford II•HCl. In antibacterial assays, II•HCl exhibited min. inhibitory concns. of 0.13-2.0 μg/mL against an assortment of Gram neg. and Gram pos. organisms, as well as ciprofloxacin resistant E. coli and S. aureus strains. In addn., II•HCl innibited supercoiling activity of DNA gyrase with IC50 of 1.0 μM.

IT **351360-04-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 3-aminoquinazoline-2,4-dione antibacterial agents via multi-step syntheses involving cyclization of benzoylhydrazinecarboxylates with phosgene)

RN 351360-04-8 ZCAPLUS

CN Carbamic acid, [1-[8-cyano-1-cyclopropyl-3-[[(1,1-dimethylethoxy)carbonyl]amino]-6-fluoro-1,2,3,4-tetrahydro-2,4-dioxo-7-quinazolinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **351362-03-3P** **351371-54-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-aminoquinazoline-2,4-dione antibacterial agents via multi-step syntheses involving cyclization of benzoylhydrazinecarboxylates with phosgene)

RN 351362-03-3 ZCAPLUS

CN 8-Quinazolinecarbonitrile, 3-amino-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,2,3,4-tetrahydro-2,4-dioxo-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 351371-54-5 ZCAPLUS

CN 8-Quinazolinecarbonitrile, 3-amino-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,2,3,4-tetrahydro-2,4-dioxo- (CA INDEX NAME)

L33 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2010 ACS on STN (Continued)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 10:22:15 ON 01 JUL 2010)

     FILE 'REGISTRY' ENTERED AT 10:22:31 ON 01 JUL 2010
L1             STR
L2           50 L1
L3             STR L1
L4           50 L3
L5         1668 L3 FULL
               SAV TEM J088C1/A L5

     FILE 'ZCAPLUS' ENTERED AT 10:26:17 ON 01 JUL 2010
L6             1 US20070191333 /PN
L7             TRA L6 1- RN :      346 TERMS

     FILE 'REGISTRY' ENTERED AT 10:26:26 ON 01 JUL 2010
L8           346 SEA L7
L9           226 L5 AND L8
L10         1442 L5 NOT L9
L11            STR L3
L12           14 L11 SAM SUB=L5
L13          233 L11 FULL SUB=L5
               SAV TEM J088C1N/A L13
L14          217 L13 AND L8
L15           16 L13 NOT L14

     FILE 'ZCAPLUS' ENTERED AT 13:26:54 ON 01 JUL 2010
L16            1 L14
L17            3 L15
L18            1 L17 AND (PD<=20031118 OR AD<=20031118 OR PRD<=20031118)
L19            1 L18 AND PD<=20021118
L20            2 L17 NOT L18-19
L21            1 L18,L19
               SEL HIT RN L21

     FILE 'REGISTRY' ENTERED AT 13:28:59 ON 01 JUL 2010
L22            3 E1-3
L23            STR
L24            STR L23
L25           15 L24
L26          265 L24 FULL
               SAV TEM J088C1B/A L26
L27          245 L26 AND L8
L28           20 L26 NOT L27

     FILE 'ZCAPLUS' ENTERED AT 13:44:00 ON 01 JUL 2010
L29            1 L27
L30            1 L16,L29
L31            4 L28
L32            1 L31 AND (PD<=20031118 OR AD<=20031118 OR PRD<=20031118)
L33            4 L31-32

=>
```